首页> 外文期刊>Drug Design, Development and Therapy >Formulation and in vitro and in vivo evaluation of film-coated montelukast sodium tablets using Opadry? yellow 20A82938 on an industrial scale
【24h】

Formulation and in vitro and in vivo evaluation of film-coated montelukast sodium tablets using Opadry? yellow 20A82938 on an industrial scale

机译:使用欧巴代(Opadry)的薄膜衣孟鲁司特钠片的配制及体内外评价黄色20A82938工业规模

获取原文
       

摘要

Purpose: The aim of this study was to formulate stable film-coated montelukast sodium (MS) tablets using Opadry? yellow 20A82938 (Montikast? tablets) and to evaluate their in vitro and in vivo release profile.Methods: MS core tablets were manufactured using a direct compression method. Opadry yellow 20A82938 aqueous coating dispersion was used as the film-coating material. Dissolution of the film-coated tablets was tested in 900 mL of 0.5% sodium lauryl sulfate solution and the bioequivalence of the tablets was tested by comparing them with a reference formulation – Singulair? tablets. In vitro–in vivo correlation was evaluated. The stability of the obtained film-coated tablets was evaluated according to International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guidelines.Results: The efficiency of the film coating was determined by subjecting the coated tablets to gastric pH and drug release was analyzed using high-performance liquid chromatography. The coated tablets had no obvious defects. MS release met the study criterion of not less than 80% dissolved after 30 minutes in 0.5% sodium lauryl sulfate solution. Statistical comparison of the main pharmacokinetic parameters clearly indicated no significant difference between test and reference in any of the calculated pharmacokinetic parameters. Level A correlation between in vitro drug release and in vivo absorption was found to be satisfactory.Conclusion: These findings suggest that aqueous film coating with Opadry yellow 20A82938 is an easy, reproducible, and economical approach for preparing stable MS film-coated tablets without affecting the drug-release characteristics.
机译:目的:本研究的目的是使用欧巴代(Opadry)配制稳定的膜衣孟鲁司特钠(MS)片剂。黄色20A82938(Montikast?片剂)并评估其体外和体内释放曲线。方法:MS核心片剂采用直接压片法制造。欧巴代黄20A82938水性涂料分散液用作薄膜包衣材料。在900 mL的0.5%月桂基硫酸钠溶液中测试了薄膜包衣片剂的溶解度,并通过将其与参考制剂– Singulair?进行比较,测试了片剂的生物等效性。平板电脑。评估了体内外相关性。根据国际人用药品注册技术要求协调会指南对获得的薄膜衣片的稳定性进行了评估。结果:薄膜衣的效率是通过使衣片经受胃液pH和药物释放来确定的用高效液相色谱法分析。包衣片剂没有明显的缺陷。 MS释放符合研究标准,即在0.5%月桂基硫酸钠溶液中放置30分钟后,溶解度不少于80%。主要药代动力学参数的统计比较清楚地表明,在任何计算出的药代动力学参数中,测试和参考之间均无显着差异。结论:欧巴代黄20A82938的水膜包衣是制备稳定的MS膜包衣片剂而又不影响药物的简便,可重现和经济的方法。药物释放特性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号